Willow Biosciences Inc. (CSE: WLLW) Enters Agreement with Noramco Inc. for Biosynthesis Platform
Willow has entered a joint development agreement with Noramco Inc. that includes a plan to develop a yeast-based biosynthesis platform to produce low-cost CBD for the pharmaceutical, food, beverage and personal care markets The agreement has the potential to open the door to new and larger markets for CBD and related compounds Terms of the agreement call for the parties to cover their own costs, retain their own intellectual property (IP) and share equally in gross profits Willow Biosciences Inc. (CSE: WLLW) has entered a joint development agreement (“JDA”) with Noramco Inc. to develop a biosynthesis platform for the production…

















